

Supplementary Figure S3. Meta-analytic summary of efficacy and safety outcomes after sensitivity analysis based on the follow-up duration of studies


S3A. Mortality




S3B. Ventilatory Support



S3C. ICU Admission



S3D. Length of hospital stay



S3E. Adverse events

	Colchicine		Supportive care			Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
Deftereos 2020	43	55	15	50	41.0%	2.61 [1.67, 4.07]	-
Tardif 2021	532	2235	344	2253	59.0%	1.56 [1.38, 1.76]	•
Total (95% CI)		2290		2303	100.0%	1.92 [1.17, 3.16]	•
Total events	575		359				
Heterogeneity: Tau ² = Test for overall effect:				0.02 0.1 1 10 50			
restroi overali ellect.	2-2.55	r – 0.0	10)				Favours [colchicine] Favours [supportive care]

S3F. Serious adverse event

	Colchic	ine	Supportive care		Risk Difference		Risk Difference
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Deftereos 2020	0	55	0	50	2.3%	0.00 [-0.04, 0.04]	
Tardif 2021	108	2235	139	2253	97.7%	-0.01 [-0.03, -0.00]	
Total (95% CI)		2290		2303	100.0%	-0.01 [-0.03, -0.00]	•
Total events	108		139				
Heterogeneity: Chi²=	0.49, df=	1 (P =	0.48); $I^2 = 09$	-02 -01 0 01 02			
Test for overall effect:	Z=1.96 (P = 0.0	5)	-0.2 -0.1 0 0.1 0.2 Favours [colchicine] Favours [supportive care]			

S3G.Diarrhoea adverse event

	Colchicine		Supportive care		Risk Ratio		Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI	
Deftereos 2020	25	55	9	50	5.6%	2.53 [1.31, 4.88]	 -	
Tardif 2021	300	2235	161	2253	94.4%	1.88 [1.57, 2.25]	=	
Total (95% CI)		2290		2303	100.0%	1.91 [1.61, 2.28]	•	
Total events	325		170					
Heterogeneity: Chi²=	0.72, df=	1 (P =	0.40); $I^2 = 0.9$	01 02 05 1 2 5 10				
Test for overall effect: $Z = 7.24$ (P < 0.00001)							Favours (colchicine) Favours (supportive care)	